Completed PHASE2 INTERVENTIONAL 4-arm NCT01011049

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Safety and Immunogenicity of Revaccination With Influenza Vaccine in Healthy Adult Subjects Aged 18 to 64 Years Who Were Previously Vaccinated With Fluzone ID or Fluzone IM

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions Influenza

Interventions Influenza Virus Vaccine USP Trivalent Types A and B

Updated 7 times since 2017 Last updated: Apr 12, 2016 Started: Sep 30, 2009 Primary completion: May 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Influenza, this trial is completed. The trial is conducted by Sanofi Pasteur, a Sanofi Company and has accumulated 7 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi Pasteur, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Allentown, United States , Austin, United States , Bensalem, United States , Binghamton, United States , Boise, United States , Cary, United States , Chandler, United States , Chicago, United States , Cincinnati, United States and 32 more locations